- Home
- CDLR vs VCEL Comparison
CDLR vs VCEL Comparison
Compare CDLR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDLR | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CDLR | VCEL |
|---|---|---|
| Price | $28.00 | $36.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 62.0K | ★ 468.5K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $53.56 | $19.40 |
| Revenue Next Year | $32.79 | $18.24 |
| P/E Ratio | ★ $7.39 | $110.80 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $15.37 | $28.95 |
| 52 Week High | $28.25 | $45.97 |
Technical Indicators
Market Signals| Indicator | CDLR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.36 | 57.26 |
| Support Level | $20.09 | $34.47 |
| Resistance Level | N/A | $38.48 |
| Average True Range (ATR) | 0.56 | 1.66 |
| MACD | 0.23 | 0.10 |
| Stochastic Oscillator | 84.66 | 74.03 |
Price Performance
Historical ComparisonAbout CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.